Momenta Pharmaceuticals (MNTA) Announces Results From a Phase 1 Study of M118 Administered as a Subcutaneous Injection

July 29, 2008 2:14 PM EDT Send to a Friend
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will present safety ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login